|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's Range||99.58 - 101.14|
|52 Week Range||62.41 - 105.69|
|Beta (5Y Monthly)||0.19|
|PE Ratio (TTM)||41.36|
|Forward Dividend & Yield||1.03 (1.02%)|
|Ex-Dividend Date||Aug 18, 2023|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for NVO
Obese and overweight patients clamouring for Novo Nordisk’s weight-loss and diabetes drugs have helped the Danish drugmaker grow into Europe’s largest company. Now, it wants to go a step further and stop people gaining weight in the first place. Novo Nordisk chief executive Lars Fruergaard Jørgensen has set his eyes on another “gold mine”: trial data that could offer clues on why some people are more likely to gain weight, and perhaps even lead to the first drugs designed to prevent obesity.
From the boom in big tech stocks fueled by enthusiasm for developments in AI to historic strikes by workers for better wages, we take a look back at just a few of the forces that shaped 2023, in charts.
Centene's (CNC) Arizona subsidiary has been chosen by the AHCCCS to improve health outcomes for the state's ALTCS-E/PD members and further solidify statewide presence.